Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.42 |
| ▸ | MC4R | P32245 | 6/20 | 0.41 |
| ▸ | MC5R | P33032 | 6/20 | 0.41 |
| ▸ | MC3R | P41968 | 6/20 | 0.41 |
| ▸ | MC1R | Q01726 | 6/20 | 0.41 |
| ▸ | ITGAV | P06756 | 2/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.41 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19362491 | 0.90 | FOLH1 (0.47) | CACNA1BELANEITGB3ITGA2BMC4R | |
| SCHEMBL16900217 | 0.88 | CACNA1B (0.41) | CACNA1BELANEITGB3ITGA2BMC4R | |
| SCHEMBL12019300 | 0.87 | ITGB3 (0.46) | CACNA1BELANEITGB3ITGA2BMC4R | |
| SCHEMBL17178028 | 0.85 | ITGB3 (0.46) | CACNA1BELANEITGB3ITGA2BMC4R | |
| SCHEMBL18022821 | 0.85 | ITGB3 (0.40) | CACNA1BELANEITGB3ITGA2BMC4R | |
| SCHEMBL19362494 | 0.84 | ITGB3 (0.50) | CACNA1BELANEITGB3ITGA2BMC4R | |
| SCHEMBL18022819 | 0.83 | CACNA1B (0.40) | CACNA1BELANEITGB3ITGA2BMC4R | |
| SCHEMBL29393726 | 0.80 | ITGB3 (0.59) | CACNA1BITGB3ITGA2BMC4RMC5R | |
| SCHEMBL16301538 | 0.78 | ITGB3 (0.55) | CACNA1BITGB3ITGA2BMC4RMC5R | |
| SCHEMBL16135240 | 0.78 | ITGB3 (0.54) | CACNA1BITGB3ITGA2BMC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353120-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-05-31 | — | — | US | disclosed |
| US-20150291608-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-10-15 | — | — | US | disclosed |
| US-9061078-B2 | Tetraaza macrocyclic compound, preparation method thereof and use thereof | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-06-23 | — | — | US | disclosed |
| US-20120219495-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291608-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | TBCA, NBAS, BMP2 | CACNA1B 1226/4885ELANE 3646/4885ITGB3 3342/4885 |
| US-20120219495-A1 | NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | TBCA, NBAS, BMP2 | CACNA1B 1226/4885ELANE 3646/4885ITGB3 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.